Fifteen-year follow-up study of Rebif patients published
Fifteen-year follow-up study of Rebif patients published
Re: Fifteen-year follow-up study of Rebif patients published
After searching elsewhere I found the original:
http://jnnp.bmj.com/content/early/2015/ ... 4.full.pdf
I went to the end of that paper, found this:
"Competing interests
All authors have completed the Unified Competing Interests form at http://icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: LK’s
Institution (University Hospital Basel) has
received and used exclusively for research support: steering committee, advisory
board and consultancy fees from Actelion, Addex, Bayer HealthCare, Biogen, Biotica,
Genzyme, Lilly, Merck, Mitsubishi, Novartis, Ono Pharma, Pfizer, Receptos, Sanofi-Aventis, Santhera, Siemens, Teva, UCB and Xenoport; speaker fees from Bayer HealthCare, Biogen, Merck, Novartis, Sanofi-Aventis and Teva; support of educational activities from Bayer HealthCare, Biogen, CSL Behring, Genzyme, Merck, Novartis, Sanofiand Teva; royalties from Neurostatus Systems GmbH; and grants from Bayer HealthCare, Biogen, Merck, Novartis, Roche, the Swiss Multiple Sclerosis
Society, the Swiss National Research Foundation, the European Union and Roche Research Foundations. JK has received research support from Bayer, Biogen Idec, Novartis and Roche. JM has received consultation/lecture fees and congress fees from Bayer, Biogen Idec, Merck Serono and Sanofi-Aventis; consultation fees from Almirall; and congress fees from Novartis and Orion. MK has received consultation/lecture fees and congress fees from Bayer, Biogen Idec, Merck Serono and
Sanofi-Aventis; congress fees from Novartis; and institutional research support from
Merck Serono, Sanofi-Aventis and Biogen Idec. EVdC, PC, LL, FC-S and DI were
salaried employees of Merck Serono SA Geneva, Switzerland, at the time of the
study. BMJU has received consultation fees from Novartis, Merck Serono, Biogen
Idec, Synthon and Danone Research
I declined from investing time to study this masterpiece of contemporary neurological "research"... PR...
MSUK wrote:EMD Serono, the American biopharmaceutical business of Merck KGaA, Darmstadt, Germany, has announced that the Journal of Neurology, Neurosurgery and Psychiatry (JNNP) has published 15-year follow-up data for Rebif, the company's high-dose, high-frequency beta interferon for relapsing-remitting multiple sclerosis (RRMS), from the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) trial... Read more - http://www.ms-uk.org/MSnews
-
- Similar Topics
- Replies
- Views
- Last post
-
- 2 Replies
- 305 Views
-
Last post by clarentine
Fri Oct 18, 2019 9:17 am
-
-
Five-Year Longitudinal Study of Neck Vessel Area
by frodo » Mon Jul 30, 2018 3:44 pm » in Chronic Cerebrospinal Venous Insufficiency (CCSVI) - 0 Replies
- 1104 Views
-
Last post by frodo
Mon Jul 30, 2018 3:44 pm
-
-
-
Study - 93.7% improvement in patients treated with cannabis
by MSUK » Wed Feb 21, 2018 4:54 am » in General Discussion - 0 Replies
- 956 Views
-
Last post by MSUK
Wed Feb 21, 2018 4:54 am
-
-
-
A REMARABLE NEW STUDY SHOWS STEMCELLS CAN REVERSE M.S IN SOME PATIENTS
by seeva » Wed Jan 16, 2019 10:54 pm » in Stem Cells - 0 Replies
- 595 Views
-
Last post by seeva
Wed Jan 16, 2019 10:54 pm
-
-
- 16 Replies
- 2389 Views
-
Last post by Kittie
Thu Feb 08, 2018 4:10 am
-
- 2 Replies
- 409 Views
-
Last post by Zyklon
Tue Jan 01, 2019 9:44 am
-
-
When to go off REBIF - went Gluten Free and Colitis healed
by dano » Tue Jan 30, 2018 4:44 pm » in General Discussion - 73 Replies
- 5449 Views
-
Last post by dano
Tue Jan 01, 2019 8:50 am
-
-
-
Sera from MS patients disrupt the BBB
by frodo » Thu May 17, 2018 9:46 pm » in MS Etiology and Pathogenesis - 0 Replies
- 734 Views
-
Last post by frodo
Thu May 17, 2018 9:46 pm
-
-
-
23% of MS patients show IgM production
by frodo » Tue Oct 01, 2019 3:34 am » in MS Etiology and Pathogenesis - 0 Replies
- 147 Views
-
Last post by frodo
Tue Oct 01, 2019 3:34 am
-